Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Immunic stock | $17.62

Own Immunic stock in just a few minutes.

Fact checked

Immunic, Inc is a biotechnology business based in the US. Immunic shares (IMUX) are listed on the NASDAQ and all prices are listed in US Dollars. Immunic employs 26 staff and has a market cap (total outstanding shares value) of USD$351.6 million.

How to buy shares in Immunic

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Immunic. Find the stock by name or ticker symbol: IMUX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Immunic reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$17.62, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Immunic, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Immunic. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Immunic share price

Use our graph to track the performance of IMUX stocks over time.

Immunic shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$17.62
52-week rangeUSD$4.19 - USD$20.98
50-day moving average USD$18.2182
200-day moving average USD$16.7579
Wall St. target priceUSD$60.86
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-11.305

Buy Immunic shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Immunic stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immunic price performance over time

Historical closes compared with the close of $17.62 from 2020-12-18

1 week (2021-01-07) 1.38%
1 month (2020-12-17) -3.93%
3 months (2020-10-16) -7.80%
6 months (2020-07-16) 39.29%
1 year (2020-01-16) 79.80%
2 years (2019-01-16) 7,854.85%
3 years (2018-01-16) 214.64%
5 years (2016-01-15) 103.23%

Immunic financials

Gross profit TTM USD$0
Return on assets TTM -26.89%
Return on equity TTM -36.3%
Profit margin 0%
Book value $7.861
Market capitalisation USD$351.6 million

TTM: trailing 12 months

Shorting Immunic shares

There are currently 1.0 million Immunic shares held short by investors – that's known as Immunic's "short interest". This figure is 33.4% up from 785,535 last month.

There are a few different ways that this level of interest in shorting Immunic shares can be evaluated.

Immunic's "short interest ratio" (SIR)

Immunic's "short interest ratio" (SIR) is the quantity of Immunic shares currently shorted divided by the average quantity of Immunic shares traded daily (recently around 403043.07692308). Immunic's SIR currently stands at 2.6. In other words for every 100,000 Immunic shares traded daily on the market, roughly 2600 shares are currently held short.

However Immunic's short interest can also be evaluated against the total number of Immunic shares, or, against the total number of tradable Immunic shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immunic's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Immunic shares in existence, roughly 30 shares are currently held short) or 0.0501% of the tradable shares (for every 100,000 tradable Immunic shares, roughly 50 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immunic.

Find out more about how you can short Immunic stock.

Immunic share dividends

We're not expecting Immunic to pay a dividend over the next 12 months.

Have Immunic's shares ever split?

Immunic's shares were split on a 1:40 basis on 15 April 2019. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immunic shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Immunic shares which in turn could have impacted Immunic's share price.

Immunic overview

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in Phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in Phase 2 trial to treat Crohn's disease. The company is also developing IMU-935, an inverse agonist of RORgt; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site